Axcella is combining endogenous metabolic modulators to develop powerful new medicines with the goal of addressing metabolic dysregulation by safely reprogramming cellular physiology with unprecedented multifactorial effects. Our AXA™ product candidates are designed to leverage the diversity and synergy of amino acid biology and target restoring health across a network of dysregulated pathways.
We are committed to researching and developing groundbreaking treatments for patients with unmet needs. Our AXA candidates are designed, optimized and studied using our platform. This innovative paradigm integrates preclinical studies and data from our human signal seeking and confirming studies* in a rapid, iterative process to generate candidates with a higher probability of success. Our platform has already produced a rich pipeline of multifunctional product candidates including programs in liver, muscle, CNS and other indications.
*Axcella conducts pre-IND, IRB-approved studies to evaluate the safety and tolerability of its AXA products in human subjects, or the product’s effects on the normal structure or function of the body. Therapeutic claims need to be established under IND.
